English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [3042]
News [6141]
Articles [120]
Editorials [18]
Conferences [181]
elearning [32]
Ponatinib superior to imatinib in combination with reduced-intensity...
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
Ponatinib superior to imatinib in combination with reduced-intensity chemotherapy in newly diagnosed Ph positive ALL ( Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA )
15 Jun 2023
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...
Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens,  Athens, Greece )
15 Jun 2023
Belamaf monotherapy induced rapid responses without unexpected toxicity in...
Dr Efstathios Kastritis - National and Kapodistrian University of Athens...
Belamaf monotherapy induced rapid responses without unexpected toxicity in relapsed or refractory light chain amyloidosis ( Dr Efstathios Kastritis - National and Kapodistrian University of Athens, Athens, Greece )
15 Jun 2023
Triplets for newly diagnosed unfit AML patients could be feasible with...
Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain
Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )
15 Jun 2023
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...
Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )
15 Jun 2023
The parotid gland; an unusual site of colorectal cancer metastasis
Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines
The parotid gland; an unusual site of colorectal cancer metastasis ( Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines )
14 Jun 2023
ASCO's efforts to improve global cancer care through the years
Dr Carlos Santiago Vallejos Sologuren - Oncosalud, Lima, Peru
ASCO's efforts to improve global cancer care through the years ( Dr Carlos Santiago Vallejos Sologuren - Oncosalud, Lima, Peru )
9 Jun 2023
US NCI's global health initiatives at ASCO 2023
Dr Satish Gopal - National Cancer Institute, Bethesda, USA
US NCI's global health initiatives at ASCO 2023 ( Dr Satish Gopal - National Cancer Institute, Bethesda, USA )
9 Jun 2023
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine...
Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma ( Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China )
6 Jun 2023
Talazoparib plus enzalutamide shows improvement in PFS over standard of care in...
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
6 Jun 2023
CDK4/6 inhibitors added to first line show no greater benefit when compared to...
Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands
CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )
6 Jun 2023
Extended lymph node removal does not benefit patients with clinically localised...
Dr Seth Lerner - Baylor College of Medicine, Houston, USA
Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer ( Dr Seth Lerner - Baylor College of Medicine, Houston, USA )
6 Jun 2023
<1...3536373839...254>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top